Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico

Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico

Authors

  • Carlo Della Pepa Dipartimento di Farmacologia, Università di Torino

  • Mario Eandi Dipartimento di Farmacologia, Università di Torino



DOI:

https://doi.org/10.7175/fe.v4i3.775

Abstract

Fluoxetine has been the first antidepressive agent of the class of selective serotonine reuptake inhibitors (SSRI) to be introduced in therapy, back in 1987. The availability of SSRIs has meant a great advance in the treatment of major depression and other neuro-psychiatric pathologies. In this paper we review the scientific and clinical research on fluoxetine that has been published in the last six years, as the prior work has been extensively examined in a review conducted on the tenth anniversary of its introduction on the market. The review focuses on cost minimization strategies that can be conducted following the introduction of low cost generic fluoxetine.

Downloads

Published

2003-09-15

How to Cite

Della Pepa, C., & Eandi, M. (2003). Fluoxetina: profilo terapeutico e farmacoeconomico di un prodotto generico. Farmeconomia. Health Economics and Therapeutic Pathways, 4(3), 125–152. https://doi.org/10.7175/fe.v4i3.775

Issue

Section

Review (Economic Analysis)

Most read articles by the same author(s)

<< < 1 2 3 4 5 6 7 8 > >> 
Loading...